News Release - July 19, 2010

Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint

Source: Abbott

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.